共 50 条
Midregional Pro-A-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Suspected Acute Myocardial Infarction
被引:12
|作者:
Meune, Christophe
[1
,3
]
Twerenbold, Raphael
[1
,2
]
Drexler, Beatrice
[1
,2
]
Balmelli, Cathrin
[1
]
Wolf, Claudia
[1
,2
]
Haaf, Philip
[1
,2
]
Reichlin, Tobias
[1
,2
]
Irfan, Affan
[1
]
Reiter, Miriam
[1
,2
]
Zellweger, Christa
[1
,2
]
Meissner, Julia
[1
]
Stelzig, Claudia
[1
]
Freese, Michael
[1
]
Capodarve, Isabel
[4
,5
]
Mueller, Christian
[1
,2
]
机构:
[1] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland
[3] Paris Descartes Univ, Cochin Hosp, APHP, Dept Cardiol, Paris, France
[4] UPF, CIBERES, ISC 3, Hosp del Mar IMIM,Serv Pneumol, Barcelona, Spain
[5] Hosp del Mar IMIM, Serv Urgencias, Barcelona, Spain
来源:
基金:
瑞士国家科学基金会;
关键词:
ACUTE CORONARY SYNDROME;
TIMI RISK SCORE;
CHEST-PAIN POPULATION;
ST-SEGMENT ELEVATION;
LONG-TERM SURVIVAL;
EMERGENCY-DEPARTMENT;
STRATIFICATION;
ISCHEMIA;
PLASMA;
BIOMARKERS;
D O I:
10.1016/j.amjcard.2011.11.047
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
We hypothesized that midregional pro-A-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multi-center study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p < 0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p < 0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p < 0.001), 0.425 (p < 0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012; 109:1117-1123)
引用
收藏
页码:1117 / 1123
页数:7
相关论文